Stage III Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 3 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02224781Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaTreatment
NCT02506153High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryTreatment